Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

This study has been completed.
Information provided by:
Peregrine Pharmaceuticals Identifier:
First received: July 27, 2007
Last updated: August 3, 2011
Last verified: August 2011

RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out." This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.

PURPOSE: This trial is studying the safety and radiation distribution of Cotara® in patients with recurrent glioblastoma multiforme.

Condition Intervention Phase
Recurrent Glioblastoma Multiforme
Drug: 131-I-chTNT-1/B MAB
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme

Resource links provided by NLM:

Further study details as provided by Peregrine Pharmaceuticals:

Primary Outcome Measures:
  • To confirm dose limit and maximum tolerated dose and to characterize radiation distribution

Estimated Enrollment: 12
Study Start Date: November 2006
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
1.5 mCi/cc
Drug: 131-I-chTNT-1/B MAB
The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
Other Name: Cotara
Experimental: 2
2.0 mCi/cc
Drug: 131-I-chTNT-1/B MAB
The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
Other Name: Cotara
Experimental: 3
2.5 mCi/cc
Drug: 131-I-chTNT-1/B MAB
The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
Other Name: Cotara

Detailed Description:



  • To confirm the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of 131I-chTNT-1/B MAb (Cotara®) when given as a single 25 hour interstitial infusion in patients with recurrent GBM
  • To characterize the biodistribution and radiation dosimetry of Cotara®


This is an open-label, dose escalation study of Cotara®.

All patients will receive 3 mCi of Cotara® for biodistribution and radiation dosimetry purposes. In addition, patients will receive escalating therapeutic dose levels of Cotara® for confirmation of the maximum tolerated dose (MTD). After completion of study treatment, patients are followed for a minimum of 12 weeks and until disease progression.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with recurrent GBM
  • Patients with a Clinical Target Volume between 5 and 60 cc (inclusive)
  • Patients of 18 years of age or older
  • Karnofsky Performance Status ≥ 60 at screening
  • Patients not on steroids or maintained on a stable corticosteroid regimen (± 4 mg) for at least 2 weeks prior to study entry

Exclusion Criteria:

  • Patients with infratentorial tumor(s), exophytic intra-ventricular tumor(s) or subependymal tumor spread extending greater than 2 cm
  • Patients with diffuse disease
  • Patients with known or suspected allergy to study medication or iodine
  • Patients who received investigational agents within 30 days prior to baseline
  • Patients who received surgical resection within 4 weeks from baseline
  • Patients with known HIV or evidence of active hepatitis
  • Patients who cannot undergo MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00509301

United States, Arizona
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
United States, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Peregrine Pharmaceuticals
Principal Investigator: Sunil J Patel, MD Medical University of South Carolina
Principal Investigator: Kenneth M Spicer, MD PhD Medical University of South Carolina
Principal Investigator: Kevin D Judy, MD University of Pennsylvania
Principal Investigator: William R Shapiro, MD Barrow Neurological Institute
Principal Investigator: Andrew E Sloan, MD, FACS University Hospitals Cleveland Medical Center
  More Information

Responsible Party: Jennifer Lai, MBA, CCRA, Peregrine Pharmaceuticals Identifier: NCT00509301     History of Changes
Obsolete Identifiers: NCT00516789
Other Study ID Numbers: PPHM 0602
Study First Received: July 27, 2007
Last Updated: August 3, 2011

Keywords provided by Peregrine Pharmaceuticals:
brain cancer
radioactive isotope
monoclonal antibody
radiation distribution

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on May 24, 2017